Clinical Trial Update: BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing risankizumab to placebo and ustekinumab in moderate to severe chronic plaque psoriasis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Risankizumab (risankizumab)
• USTEKINUMAB (USTEKINUMAB)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-06-18